Is Supernus Pharmaceuticals Stock a Good Investment?
Supernus Pharmaceuticals Investment Advice | SUPN |
- Examine Supernus Pharmaceuticals' financial health by looking at its balance sheet, income statement, and cash flow statement. Analyze key financial ratios, such as Price-to-Earnings (P/E), Price-to-Sales (P/S), and Price-to-Book (P/B), to determine whether the stock is fairly valued or over/undervalued.
- Research Supernus Pharmaceuticals' leadership team and their track record. Good management can help Supernus Pharmaceuticals navigate difficult times and make strategic decisions that benefit shareholders and increases its net worth.
- Consider the overall health of the Pharmaceuticals space and any emerging trends that could impact Supernus Pharmaceuticals' business and its evolving consumer preferences.
- Compare Supernus Pharmaceuticals' performance and market position to its competitors. Analyze how Supernus Pharmaceuticals is positioned in terms of product offerings, innovation, and market share.
- Check if Supernus Pharmaceuticals pays a dividend and its dividend yield and payout ratio.
- Review what financial analysts are saying about Supernus Pharmaceuticals' stock and their price targets. However, remember that analysts' opinions can vary, and their predictions may not always be accurate.
It's important to note that investing in Supernus Pharmaceuticals stock, carries risks, and you should carefully consider your investment goals and risk tolerance before making any investment decisions. Also, remember that it's important for investors to have a long-term perspective and a well-diversified portfolio to manage the impact of stock market volatility on their investments. Below is a detailed guide on how to decide if Supernus Pharmaceuticals is a good investment.
Sell | Buy |
Cautious Hold
Market Performance | Insignificant | Details | |
Volatility | Very steady | Details | |
Hype Condition | Low key | Details | |
Current Valuation | Undervalued | Details | |
Odds Of Distress | Low | Details | |
Economic Sensitivity | Almost mirrors the market | Details | |
Investor Sentiment | Alarmed | Details | |
Analyst Consensus | Buy | Details | |
Financial Strenth (F Score) | Healthy | Details | |
Financial Leverage | Not Rated | Details | |
Reporting Quality (M-Score) | Unlikely Manipulator | Details |
Examine Supernus Pharmaceuticals Stock
Researching Supernus Pharmaceuticals' stock involves analyzing various aspects of the company and its industry to make an informed investment decision. The key areas to focus on are fundamentals, business model and competitive advantage. It is also important to analyze trends in revenue, net income, and cash flow, as well as key financial ratios, such as price-to-earnings (P/E), price-to-sales (P/S), and debt-to-equity (D/E). About 95.0% of the company shares are owned by institutional investors. The company has price-to-book ratio of 1.99. Typically companies with comparable Price to Book (P/B) are able to outperform the market in the long run. Supernus Pharmaceuticals has Price/Earnings To Growth (PEG) ratio of 1.47. The entity had not issued any dividends in recent years.
To determine if Supernus Pharmaceuticals is a good investment, evaluating the company's potential for future growth is also very important. This may include expanding into new markets, launching new products or services, or improving operational efficiency. Companies with strong growth prospects can be more attractive investments. This aspect of the research should be conducted in the context of the overall market and industry in which the company operates and should include an analysis of growth potential, competitive landscape, and any regulatory or economic factors that could impact the business. Some of the essential points regarding Supernus Pharmaceuticals' research are outlined below:
| Supernus Pharmaceuticals currently holds 41.53 M in liabilities with Debt to Equity (D/E) ratio of 0.53, which is about average as compared to similar companies. Supernus Pharmaceuticals has a current ratio of 0.83, indicating that it has a negative working capital and may not be able to pay financial obligations when due. Note, when we think about Supernus Pharmaceuticals' use of debt, we should always consider it together with its cash and equity. | |
| Over 95.0% of Supernus Pharmaceuticals shares are owned by institutional investors | |
| Latest headline from news.google.com: Mutual of America Capital Management LLC Sells 75,782 Shares of Supernus Pharmaceuticals, Inc. - MarketBeat |
Supernus Pharmaceuticals Quarterly Cash And Short Term Investments |
|
Supernus Pharmaceuticals uses earnings reports to provide investors with an update of all three financial statements, including the income statement, the balance sheet, and the cash flow statement. Therefore, it is also crucial when considering investing in Supernus Pharmaceuticals. Every quarterly earnings report provides investors with an overview of sales, expenses, and net income for the most recent period. It also may provide a comparison to Supernus Pharmaceuticals' previous reporting period. The quarterly earnings reports are usually disseminated to the public via Form 10-Q, which is a legal document filed with the Securities and Exchange Commission every quarter.
| 27th of February 2024 Upcoming Quarterly Report | View | |
| 14th of May 2024 Next Financial Report | View | |
| 31st of December 2023 Next Fiscal Quarter End | View | |
| 27th of February 2024 Next Fiscal Year End | View | |
| 30th of September 2023 Last Quarter Report | View | |
| 31st of December 2022 Last Financial Announcement | View |
Earnings surprises can significantly impact Supernus Pharmaceuticals' stock price both in the short term and over time. Negative earnings surprises usually result in a price decline. However, it has been seen that positive earnings surprises lead to an immediate rise in a stock's price and a gradual increase over time. This is why we often hear news about some companies beating earning projections. Financial analysts spend a large amount of time predicting earnings per share (EPS) along with other important future indicators. Many analysts use forecasting models, management guidance, and additional fundamental information to derive an EPS estimate. Below are the table of largest EPS Surprises Supernus Pharmaceuticals' investors have experienced.
| Reported | Fiscal Date | Estimated EPS | Reported EPS | Surprise | |||
|---|---|---|---|---|---|---|---|
2016-05-03 | 2016-03-31 | 0.09 | 0.08 | -0.01 | 11 | ||
2015-08-04 | 2015-06-30 | 0.02 | 0.03 | 0.01 | 50 | ||
2017-05-09 | 2017-03-31 | 0.22 | 0.19 | -0.03 | 13 | ||
2015-05-05 | 2015-03-31 | -0.01 | 0.02 | 0.03 | 300 | ||
2024-08-06 | 2024-06-30 | 0.31 | 0.36 | 0.05 | 16 | ||
2016-08-02 | 2016-06-30 | 0.13 | 0.18 | 0.05 | 38 | ||
2019-11-05 | 2019-09-30 | 0.6 | 0.54 | -0.06 | 10 | ||
2015-11-03 | 2015-09-30 | 0.02 | 0.08 | 0.06 | 300 |
Know Supernus Pharmaceuticals' Top Institutional Investors
Have you ever been surprised when a price of an equity instrument such as Supernus Pharmaceuticals is soaring high without any particular reason? This is usually happening because many institutional investors are aggressively trading Supernus Pharmaceuticals backward and forwards among themselves. Supernus Pharmaceuticals' institutional investor refers to the entity that pools money to purchase Supernus Pharmaceuticals' securities or originate loans. Institutional investors include commercial and private banks, credit unions, insurance companies, pension funds, hedge funds, endowments, and mutual funds. Operating companies that invest excess capital in these types of assets may also be included in the term and may influence corporate governance by exercising voting rights in their investments.
| Shares | Pacer Advisors, Inc. | 2024-06-30 | 1.3 M | Morgan Stanley - Brokerage Accounts | 2024-06-30 | 1.3 M | Gw&k Investment Management, Llc | 2024-09-30 | 1.2 M | Aristotle Capital Boston, Llc | 2024-06-30 | 1.2 M | American Century Companies Inc | 2024-09-30 | 1 M | Victory Capital Management Inc. | 2024-09-30 | 742.9 K | Charles Schwab Investment Management Inc | 2024-09-30 | 712.4 K | Ashford Capital Management Inc | 2024-06-30 | 711.9 K | Northern Trust Corp | 2024-09-30 | 606.3 K | Blackrock Inc | 2024-06-30 | 10.4 M | Vanguard Group Inc | 2024-09-30 | 6.1 M |
Supernus Pharmaceuticals' market capitalization trends
The company currently falls under 'Mid-Cap' category with a current market capitalization of 2 B.Market Cap |
|
Supernus Pharmaceuticals' profitablity analysis
| Last Reported | Projected for Next Year | ||
| Return On Capital Employed | (0.01) | (0.01) |
Determining Supernus Pharmaceuticals' profitability involves analyzing its financial statements and using various financial metrics to determine if Supernus Pharmaceuticals is a good buy. For example, gross profit margin measures Supernus Pharmaceuticals' profitability after accounting for the cost of goods sold, while net profit margin measures profitability after accounting for all expenses. Other important metrics include return on assets, return on equity, and free cash flow. By reviewing multiple sources and metrics, you can gain a complete picture of Supernus Pharmaceuticals' profitability and make more informed investment decisions.
Evaluate Supernus Pharmaceuticals' management efficiency
Supernus Pharmaceuticals has return on total asset (ROA) of 0.0289 % which means that it generated a profit of $0.0289 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of 0.0622 %, meaning that it created $0.0622 on every $100 dollars invested by stockholders. Supernus Pharmaceuticals' management efficiency ratios could be used to measure how well Supernus Pharmaceuticals manages its routine affairs as well as how well it operates its assets and liabilities. At this time, Supernus Pharmaceuticals' Return On Tangible Assets are very stable compared to the past year. As of the 25th of November 2024, Return On Assets is likely to grow to 0, while Return On Capital Employed is likely to drop (0.01). At this time, Supernus Pharmaceuticals' Debt To Assets are very stable compared to the past year. As of the 25th of November 2024, Fixed Asset Turnover is likely to grow to 22.16, while Total Assets are likely to drop about 676.1 M.| Last Reported | Projected for Next Year | ||
| Book Value Per Share | 16.90 | 17.74 | |
| Tangible Book Value Per Share | 3.75 | 2.04 | |
| Enterprise Value Over EBITDA | 15.72 | 16.51 | |
| Price Book Value Ratio | 1.71 | 1.51 | |
| Enterprise Value Multiple | 15.72 | 16.51 | |
| Price Fair Value | 1.71 | 1.51 | |
| Enterprise Value | 1.5 B | 1.6 B |
Effective leadership at Supernus Pharmaceuticals drives its competitive edge in the market. Our analysis focuses on how this translates to financial performance and stock value.
Beta 0.866 |
Basic technical analysis of Supernus Stock
As of the 25th of November, Supernus Pharmaceuticals has the Semi Deviation of 1.98, coefficient of variation of 2109.68, and Risk Adjusted Performance of 0.0426. In relation to fundamental indicators, the technical analysis model makes it possible for you to check existing technical drivers of Supernus Pharmaceuticals, as well as the relationship between them.Supernus Pharmaceuticals' insider trading activities
Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Supernus Pharmaceuticals insiders, such as employees or executives, is commonly permitted as long as it does not rely on Supernus Pharmaceuticals' material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases Supernus Pharmaceuticals insiders are required to file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
Supernus Pharmaceuticals' Outstanding Corporate Bonds
Supernus Pharmaceuticals issues bonds to finance its operations. Corporate bonds make up one of the largest components of the U.S. bond market, which is considered the world's largest securities market. Supernus Pharmaceuticals uses the proceeds from bond sales for a wide variety of purposes, including financing ongoing mergers and acquisitions, buying new equipment, investing in research and development, buying back their own stock, paying dividends to shareholders, and even refinancing existing debt. Most Supernus bonds can be classified according to their maturity, which is the date when Supernus Pharmaceuticals has to pay back the principal to investors. Maturities can be short-term, medium-term, or long-term (more than ten years). Longer-term bonds usually offer higher interest rates but may entail additional risks.
| Boeing Co 2196 Corp BondUS097023DG73 | View | |
| HSBC Holdings PLC Corp BondUS404280DR76 | View | |
| MGM Resorts International Corp BondUS552953CD18 | View | |
| AerCap Global Aviation Corp BondUS00773HAA59 | View |
Understand Supernus Pharmaceuticals' technical and predictive indicators
Using predictive indicators to make investment decisions involves analyzing Supernus Pharmaceuticals' various financial and market-based factors to help forecast future trends and identify investment opportunities. Select the indicators that are most relevant to your investment strategy. Each indicator has its own strengths and weaknesses, so it's essential to combine multiple indicators to get a more comprehensive view of the market and reduce the risk of making poor decisions based on limited data.
| Risk Adjusted Performance | 0.0426 | |||
| Market Risk Adjusted Performance | 0.0835 | |||
| Mean Deviation | 1.34 | |||
| Semi Deviation | 1.98 | |||
| Downside Deviation | 2.11 | |||
| Coefficient Of Variation | 2109.68 | |||
| Standard Deviation | 2.04 | |||
| Variance | 4.18 | |||
| Information Ratio | (0.02) | |||
| Jensen Alpha | (0.06) | |||
| Total Risk Alpha | (0.24) | |||
| Sortino Ratio | (0.02) | |||
| Treynor Ratio | 0.0735 | |||
| Maximum Drawdown | 12.87 | |||
| Value At Risk | (2.71) | |||
| Potential Upside | 2.77 | |||
| Downside Variance | 4.46 | |||
| Semi Variance | 3.93 | |||
| Expected Short fall | (1.33) | |||
| Skewness | 0.3078 | |||
| Kurtosis | 5.9 |
| Risk Adjusted Performance | 0.0426 | |||
| Market Risk Adjusted Performance | 0.0835 | |||
| Mean Deviation | 1.34 | |||
| Semi Deviation | 1.98 | |||
| Downside Deviation | 2.11 | |||
| Coefficient Of Variation | 2109.68 | |||
| Standard Deviation | 2.04 | |||
| Variance | 4.18 | |||
| Information Ratio | (0.02) | |||
| Jensen Alpha | (0.06) | |||
| Total Risk Alpha | (0.24) | |||
| Sortino Ratio | (0.02) | |||
| Treynor Ratio | 0.0735 | |||
| Maximum Drawdown | 12.87 | |||
| Value At Risk | (2.71) | |||
| Potential Upside | 2.77 | |||
| Downside Variance | 4.46 | |||
| Semi Variance | 3.93 | |||
| Expected Short fall | (1.33) | |||
| Skewness | 0.3078 | |||
| Kurtosis | 5.9 |
Consider Supernus Pharmaceuticals' intraday indicators
Supernus Pharmaceuticals intraday indicators are useful technical analysis tools used by many experienced traders. Just like the conventional technical analysis, daily indicators help intraday investors to analyze the price movement with the timing of Supernus Pharmaceuticals stock daily movement. By combining multiple daily indicators into a single trading strategy, you can limit your risk while still earning strong returns on your managed positions.
| Accumulation Distribution | 8465.17 | |||
| Daily Balance Of Power | (0.11) | |||
| Rate Of Daily Change | 1.0 | |||
| Day Median Price | 36.66 | |||
| Day Typical Price | 36.47 | |||
| Price Action Indicator | (0.61) | |||
| Period Momentum Indicator | (0.12) | |||
| Relative Strength Index | 64.51 |
Supernus Pharmaceuticals Corporate Filings
13A | 14th of November 2024 An amended filing to the original Schedule 13G | ViewVerify |
F4 | 12th of November 2024 The report filed by a party regarding the acquisition or disposition of a company's common stock, as well as derivative securities such as options, warrants, and convertible securities | ViewVerify |
8K | 4th of November 2024 Report filed with the SEC to announce major events that shareholders should know about | ViewVerify |
13A | 31st of October 2024 The form used by investors holding more than 5% of a company's stock, to report their beneficial ownership pursuant to Rule 13d-1 or Rule 13d-2 under the Securities Exchange Act of 1934 | ViewVerify |
Supernus Stock media impact
Far too much social signal, news, headlines, and media speculation about Supernus Pharmaceuticals that are available to investors today. That information is available publicly through Supernus media outlets and privately through word of mouth or via Supernus internal channels. However, regardless of the origin, that massive amount of Supernus data is challenging to quantify into actionable patterns, especially for investors that are not very sophisticated with ever-evolving tools and techniques used in the investment management field.
A primary focus of Supernus Pharmaceuticals news analysis is to determine if its current price reflects all relevant headlines and social signals impacting the current market conditions. A news analyst typically looks at the history of Supernus Pharmaceuticals relative headlines and hype rather than examining external drivers such as technical or fundamental data. It is believed that price action tends to repeat itself due to investors' collective, patterned thinking related to Supernus Pharmaceuticals' headlines and news coverage data. This data is often completely overlooked or insufficiently analyzed for actionable insights to drive Supernus Pharmaceuticals alpha.
Supernus Pharmaceuticals Sentiment by Major News Outlets
Investor sentiment, mood or attitude towards Supernus Pharmaceuticals can have a significant impact on its stock price or the market as a whole. This sentiment can be positive or negative, and various factors, such as economic indicators, news events, or market trends, can influence it. When investor sentiment is positive, investors are more likely to buy stocks, increasing demand and increasing the stock price. Positive investor sentiment can be driven by good news about the company or the broader market, such as solid earnings reports or positive economic data.
Note that negative investor sentiment can cause investors to sell stocks, leading to a decrease in demand and a drop in the stock price. Negative sentiment can be driven by factors such as poor earnings reports, negative news about the company or industry, or broader economic concerns. It's important to note that investor sentiment is just one of many factors that can affect stock prices. Other factors, such as company performance, industry trends, and global economic conditions, can also play a significant role in determining the value of a stock.
Supernus Pharmaceuticals Historical Investor Sentiment
Investor biases related to Supernus Pharmaceuticals' public news can be used to forecast risks associated with an investment in Supernus. The trend in average sentiment can be used to explain how an investor holding Supernus can time the market purely based on public headlines and social activities around Supernus Pharmaceuticals. Please note that most equities that are difficult to arbitrage are affected by market sentiment the most.
Supernus Pharmaceuticals' market sentiment shows the aggregated news analyzed to detect positive and negative mentions from the text and comments. The data is normalized to provide daily scores for Supernus Pharmaceuticals and other traded tickers. The bigger the bubble, the more accurate the estimated score. Higher bars for a given day show more participation in the average Supernus Pharmaceuticals news discussions. The higher the estimate score, the more favorable the investor's outlook on Supernus Pharmaceuticals.
Supernus Pharmaceuticals Corporate Management
| Padmanabh Bhatt | Chief Scientific Officer and Sr. VP of Intellectual Property | Profile | |
| Tami Martin | VP Affairs | Profile | |
| Jeff Bozick | Senior Chain | Profile | |
| Kevin Esq | Compliance Officer | Profile | |
| Taylor Raiford | Senior Sales | Profile | |
| Bryan Roecklein | Senior Development | Profile |
Check out World Market Map to better understand how to build diversified portfolios, which includes a position in Supernus Pharmaceuticals. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in american community survey. To learn how to invest in Supernus Stock, please use our How to Invest in Supernus Pharmaceuticals guide.You can also try the Piotroski F Score module to get Piotroski F Score based on the binary analysis strategy of nine different fundamentals.
Is Pharmaceuticals space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Supernus Pharmaceuticals. If investors know Supernus will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Supernus Pharmaceuticals listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth (0.99) | Earnings Share 1.07 | Revenue Per Share 11.877 | Quarterly Revenue Growth 0.142 | Return On Assets 0.0289 |
The market value of Supernus Pharmaceuticals is measured differently than its book value, which is the value of Supernus that is recorded on the company's balance sheet. Investors also form their own opinion of Supernus Pharmaceuticals' value that differs from its market value or its book value, called intrinsic value, which is Supernus Pharmaceuticals' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Supernus Pharmaceuticals' market value can be influenced by many factors that don't directly affect Supernus Pharmaceuticals' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
In summary, please note that there is a difference between Supernus Pharmaceuticals' value and its price, as these two are different measures arrived at by various means. Investors typically determine if Supernus Pharmaceuticals is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Supernus Pharmaceuticals' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.